Brad Hively
CIK 1891124 · Chief Executive Officer · last filed 2026-08-24
Brad Hively is a Chief Executive Officer who has filed 30 SEC Form 4 insider transactions across 2 companies since 2021. The most recent filing shows the insider sold $1.9M of TOI on Aug 24, 2026. Across all open-market trades the lifetime net is −$7.8M, making them a net seller over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
TOIIW price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
18000 STUDEBAKER ROAD, SUITE 800
CERRITOS, CA 90703
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Oncology Institute, Inc. (TOI) Delisted | Chief Executive Officer | 411,976 | $5.13 | $2.11M | -$1.95M | 6 | 2026-08-24 |
| Oncology Institute, Inc. (TOIIW) Delisted | Director | 683,721 | $0.05 | $33.5K | -$5.89M | 18 | 2025-12-16 |
Recent Filings
30 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-08-24 | Oncology Institute, Inc. (TOI) Delisted | Sell (S) | −298,853 | -$1.95M | EDGAR |
| 2026-08-21 | Oncology Institute, Inc. (TOI) Delisted | Notice (144) | −298,853 | -$1.95M | EDGAR |
| 2026-07-29 | Oncology Institute, Inc. (TOI) Delisted | Grant (A) | +27,108 | $0 | EDGAR |
| 2025-12-16 | Oncology Institute, Inc. (TOIIW) Delisted | Sell (S) | −13,333 | -$50.3K | EDGAR |
| 2025-12-15 | Oncology Institute, Inc. (TOI) Delisted | Notice (144) | −13,333 | -$50.3K | EDGAR |
| 2025-11-24 | Oncology Institute, Inc. (TOIIW) Delisted | Grant (A) | +74,074 | $0 | EDGAR |
| 2025-08-21 | Oncology Institute, Inc. (TOIIW) Delisted | Sell (S) | −20,221 | -$82.1K | EDGAR |
| 2025-06-05 | Oncology Institute, Inc. (TOIIW) Delisted | Mixed | −108,532 | -$3.99M | EDGAR |
| 2025-06-03 | Oncology Institute, Inc. (TOI) Delisted | Notice (144) | −39,600 | -$113.7K | EDGAR |
| 2025-06-03 | Oncology Institute, Inc. (TOI) Delisted | Notice (144) | −1,936,537 | -$5.56M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.